Educational Session: "The Clinical Proteomic Tumor Analysis Consortium: Resources and Data Dissemination" at the AACR Annual Meeting 2020
NCI's Clinical Proteomic Tumor Analysis Consortium (CPTAC) brings together leading scientists in the field of proteogenomics from across the nation to further our understanding of cancer biology and to accelerate precision oncology.
In this educational session, "The Clinical Proteomic Tumor Analysis Consortium: Resources and Data Dissemination", researchers will describe CPTAC's comprehensive proteomic and matching genomic tumor characterization methodologies, particularly with regard to clinical trials. Highlights include information on data access procedures, informatics tools for proteogenomics analysis, and recent advances on mass spectrometry-based targeted assays.
The following CPTAC virtual posters will be on display during the meeting:
| PO.CH03.01 | Proteomics and Biomarker Discovery |
| PO.TB02.02 | Developmental Pathways in Cancer |
| PO.ET04.04 |
Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 1 |
| PO.ET04.05 |
Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 2 |
| PO.MCB09.01 | Functional Genomics and Other Topics |
| PO.MCB09.02 | Large-Scale and High-Throughput Sequencing |
| PO.BSB01.03 | Knowledge, Networks, Graphs, and Models for Discovery |
| PO.BSB01.05 | Multi-omic and Multimodal Discovery |
| PO.BSB02.03 | Network Biology / Multi-omics |
| LBPO.CH01 | Late-Breaking Research: Cancer Chemistry |